Biotech entity
Every one of those 1 sits in a single category, clinical-trial. ZP9830 is most often covered alongside Kv1.3 channel blocker, which appears in 1 of these 1 story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. ZP9830 is most often covered alongside Kv1.3 channel blocker, which appears in 1 of these 1 story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Biotech story that mention ZP9830, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ZP9830. Shared-story counts are live from our verified record — not editorial picks.
Zealand Pharma has announced positive topline results from its Phase 1a trial of ZP9830, a novel Kv1.3 channel blocker. The study successfully met its primary objectives for safety and tolerability, paving the way for further development of this oral candidate for chronic inflammatory and autoimmune diseases.
Source: manilatimes.net · rttnews.com
ZP9830 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
